The Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients.

Samsung Medical Center

Status: Enrolling

Conditions: HER2-positive Breast Cancer

Treatments: Diagnostic Test: GeoMx data analysis with clinical outcome

Study type: Interventional

Funder types: Other

Identifiers

NCT06330012

GeoMx_Breast

Details and patient eligibility

About

This study is the spatial transcriptomic approach for revealing the resistance mechanism of trastuzumab deruxtexan in HER2 positive breast cancer patients.

Enrollment: 50 estimated patients

Sex: Female

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• HER2 positive breast cancer
• Stage IV disease
• Treated with T-Dxd
• Available FFPE samples

Exclusion criteria

• TNBC breast cancer
• Hormone receptor positive breast cancer
• Non-available FFPE samples
• Treated except T-Dxd

Trial design

Primary purpose: Screening

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

50 participants in 1 patient group

Spatial transcriptomic approch

Experimental group

Description:

Spatial transcriptomic approch for revealing the resistance mechanism of trastuzumab deruxtexan in HER2 positive breast cancer patients.

Treatment:

Diagnostic Test: GeoMx data analysis with clinical outcome